M H Le1, Y H Yeo1, R Cheung1,2, V W-S Wong3, M H Nguyen1. 1. From the, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. 2. Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care, Palo Alto, CA, USA. 3. Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a rising global disease associated with clinical and economic burdens. OBJECTIVES: We aimed to quantify NAFLD prevalence and awareness to provide stakeholders necessary information to combat NAFLD burden. METHODS: This study utilizes data from the National Health and Nutrition Examination Survey 2011-2016 and included 4538 adult participants who did not have heavy drinking or viral hepatitis history. The US fatty liver index defined NAFLD and NAFLD fibrosis score defined fibrosis. NAFLD awareness was captured by questionnaire. RESULTS: Amongst the study population of 4538 persons, NAFLD prevalence was 32.5%, lowest in non-Hispanic Blacks (18.0%) and Asians (18.1%), highest amongst Mexican Americans (48.4%). Within the NAFLD group, advanced fibrosis was highest in non-Hispanic Blacks (28.5%) and lowest amongst non-Hispanic Asians (2.7%). Of the 1473 (97.5%) NAFLD participants who answered NAFLD awareness question, 90% visited a healthcare centre at least once in the past year, but only 5.1% were aware of having NAFLD. On weighted population estimates, 77.33 million persons had NAFLD, 17.63 million had advanced fibrosis, and 73.39 million NAFLD participants were not aware of having NAFLD. CONCLUSIONS: Of 77.33 million people in the United States have NAFLD with 17.63 million having advanced fibrosis, with lowest prevalence in non-Hispanic Asians and highest in Mexican Americans. A conundrum exists amongst non-Hispanic Blacks who have low NAFLD prevalence but highest prevalence of advanced fibrosis. Awareness of NAFLD was low across all ethnicities. Effort is needed to improve disease awareness whilst addressing NAFLD clinical burden across ethnicities.
BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) is a rising global disease associated with clinical and economic burdens. OBJECTIVES: We aimed to quantify NAFLD prevalence and awareness to provide stakeholders necessary information to combat NAFLD burden. METHODS: This study utilizes data from the National Health and Nutrition Examination Survey 2011-2016 and included 4538 adult participants who did not have heavy drinking or viral hepatitis history. The US fatty liver index defined NAFLD and NAFLDfibrosis score defined fibrosis. NAFLD awareness was captured by questionnaire. RESULTS: Amongst the study population of 4538 persons, NAFLD prevalence was 32.5%, lowest in non-Hispanic Blacks (18.0%) and Asians (18.1%), highest amongst Mexican Americans (48.4%). Within the NAFLD group, advanced fibrosis was highest in non-Hispanic Blacks (28.5%) and lowest amongst non-Hispanic Asians (2.7%). Of the 1473 (97.5%) NAFLDparticipants who answered NAFLD awareness question, 90% visited a healthcare centre at least once in the past year, but only 5.1% were aware of having NAFLD. On weighted population estimates, 77.33 million persons had NAFLD, 17.63 million had advanced fibrosis, and 73.39 million NAFLDparticipants were not aware of having NAFLD. CONCLUSIONS: Of 77.33 million people in the United States have NAFLD with 17.63 million having advanced fibrosis, with lowest prevalence in non-Hispanic Asians and highest in Mexican Americans. A conundrum exists amongst non-Hispanic Blacks who have low NAFLD prevalence but highest prevalence of advanced fibrosis. Awareness of NAFLD was low across all ethnicities. Effort is needed to improve disease awareness whilst addressing NAFLD clinical burden across ethnicities.
Authors: Sri Lekha Tummalapalli; Eric Vittinghoff; Deidra C Crews; Mary Cushman; Orlando M Gutiérrez; Suzanne E Judd; Holly J Kramer; Carmen A Peralta; Delphine S Tuot; Michael G Shlipak; Michelle M Estrella Journal: Am J Nephrol Date: 2020-04-29 Impact factor: 3.754
Authors: Javier A Tamargo; Kenneth E Sherman; Adriana Campa; Sabrina S Martinez; Tan Li; Jacqueline Hernandez; Colby Teeman; Raul N Mandler; Jun Chen; Richard L Ehman; Marianna K Baum Journal: Am J Clin Nutr Date: 2021-03-11 Impact factor: 8.472
Authors: Vincent L Chen; Ming-Lun Yeh; Ju Dong Yang; Jennifer Leong; Daniel Q Huang; Hidenori Toyoda; Yao-Li Chen; Jennifer Guy; Mayumi Maeda; Pei-Chien Tsai; Chung-Feng Huang; Satoshi Yasuda; An K Le; Hansen Dang; Nasra H Giama; Hamdi A Ali; Ning Zhang; Xiaozhong Wang; Dae Won Jun; Cheng-Hao Tseng; Yao-Chun Hsu; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Qiang Zhu; Yock Young Dan; Myron Schwartz; Lewis R Roberts; Ming-Lung Yu; Mindie H Nguyen Journal: Hepatol Commun Date: 2020-09-24
Authors: Emily Truong; Yee Hui Yeo; Galen Cook-Wiens; Mark Muthiah; Ju Dong Yang; Vinay Sundaram; Devon Chang; Tsuyoshi Todo; Irene K Kim; Shelly C Lu; Veronica Wendy Setiawan; Vincent W S Wong; Stephen A Harrison; Naim Alkhouri; Mazen Noureddin Journal: Hepatol Commun Date: 2022-05-09
Authors: C Louwrens Braal; Robert J de Knegt; Agnes Jager; Stijn L W Koolen; Ron H J Mathijssen; Karel Eechoute Journal: Hepatol Commun Date: 2022-06-10